查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703438

兩性黴素 B 市場 - 全球產業規模、佔有率、趨勢、機會和預測（按銷售管道、最終用途、地區和競爭細分，2020-2030 年）

Amphotericin B Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球兩性黴素 B 市值為 6,941 萬美元，預計到 2030 年將達到 1.0554 億美元，預測期內的年複合成長率(CAGR) 為 2.91%。市場正在經歷持續成長，主要原因是全球危及生命的真菌感染發病率上升以及免疫功能低下人群數量的增加。兩性黴素 B 是一種多烯抗真菌劑，仍是治療嚴重全身性真菌疾病（包括隱球菌腦膜炎、麴菌病、毛黴菌病和念珠菌病）最有效的藥物之一。儘管出現了較新的抗真菌藥物，兩性黴素 B 仍然保持著重要的治療意義，特別是在醫院環境和多重抗藥性病例中。推動市場成長的關鍵因素是免疫功能低下患者（例如接受化療、器官移植或感染愛滋病毒/愛滋病的患者）中機會性真菌感染的盛行率不斷上升。毛黴菌病病例的增加，尤其是在某些地區 COVID-19 疫情期間，進一步增加了對兩性黴素 B 的需求。此外，脂質體和脂質複合物製劑的進步提高了藥物耐受性並降低了腎毒性，進一步提高了臨床應用率。發展中經濟體醫療保健服務的擴大和意識的增強也推動了抗真菌療法的廣泛使用，從而增強了市場潛力。

市場概覽
預測期 2026-2030
2024年市場規模 6941萬美元
2030年市場規模 1.0554億美元
2025-2030 年複合年成長率 2.91%
成長最快的領域 直接的
最大的市場 亞太

關鍵市場促進因素

醫療保健產業的成長：

主要市場挑戰

毒性和不良副作用：

主要市場趨勢

真菌感染盛行率不斷上升：

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球兩性黴素 B 市場的影響

第5章：全球兩性黴素B市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按銷售管道（直接、間接）
    • 依最終用途（全身性真菌感染、念珠菌病、曲霉病、毛黴菌病、利甚曼病等）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美兩性黴素B市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲兩性黴素B市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區兩性黴素B市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美兩性黴素B市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲兩性黴素B市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：全球兩性黴素 B 市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Xiamen Neore Pharmaceutical Technology Co., Ltd
  • Concord Biotech Limited
  • United Biotech Pvt Ltd
  • Hubei Aoks Bio-Tech Co.,Ltd
  • Synbiotics Limited
  • North China Pharmaceutical Huasheng Co., Ltd
  • Xi'an Sonwu Biotech Co., Ltd.
  • Century Pharmaceutical Ltd
  • Xellia Pharmaceuticals

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 28279

Global Amphotericin B market was valued at USD 69.41 million in 2024 and is projected to reach USD 105.54 million by 2030, growing at a compound annual growth rate (CAGR) of 2.91% during the forecast period. The market is experiencing consistent growth, primarily driven by the rising incidence of life-threatening fungal infections and the expanding population of immunocompromised individuals worldwide. Amphotericin B, a polyene antifungal agent, remains one of the most effective treatments for severe systemic mycoses, including cryptococcal meningitis, aspergillosis, mucormycosis, and candidiasis. Despite the emergence of newer antifungal agents, Amphotericin B continues to maintain significant therapeutic relevance, especially in hospital settings and in cases of multidrug resistance. A key factor contributing to the market's growth is the increasing prevalence of opportunistic fungal infections among immunocompromised patients, such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. The rise in mucormycosis cases, particularly during the COVID-19 pandemic in certain regions, has further heightened the demand for Amphotericin B. Moreover, advancements in liposomal and lipid complex formulations have improved drug tolerability and reduced nephrotoxicity, further enhancing clinical adoption. Expanding healthcare access and growing awareness in developing economies are also driving greater use of antifungal therapies, thereby enhancing market potential.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 69.41 Million
Market Size 2030USD 105.54 Million
CAGR 2025-20302.91%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

Key Market Drivers

Growth in Healthcare Industry:

The continued expansion of the global healthcare sector is a major driver of the Amphotericin B market. The global hospital market is expected to generate USD 4.41 trillion in revenue by 2025. In the United States, hospitals are making significant investments in telemedicine to extend remote healthcare services, particularly in rural areas. As healthcare systems evolve and infrastructure improves in both developed and emerging economies, there is a growing emphasis on effective treatments for life-threatening fungal infections, where Amphotericin B remains a gold standard. Known for its potent antifungal properties, Amphotericin B is widely used in managing systemic mycoses, particularly in immunocompromised patients such as those with HIV/AIDS, cancer, or undergoing organ transplants.

Key Market Challenges

Toxicity and Adverse Side Effects:

A significant challenge facing the global Amphotericin B market is the drug's known toxicity and adverse side effects. Although Amphotericin B is considered a gold standard for treating severe fungal infections, its use is often limited by safety concerns, particularly nephrotoxicity, which can lead to acute kidney injury in a significant proportion of patients. Other common adverse effects include infusion-related reactions such as fever, chills, hypotension, and electrolyte imbalances. These side effects require intensive monitoring and hospitalization, thus increasing treatment costs and complexity. While liposomal and lipid-based formulations have helped mitigate some of these toxicities, their high cost limits broader adoption, particularly in resource-limited settings. The ongoing challenge of balancing efficacy with safety remains a major concern for healthcare providers and pharmaceutical manufacturers, highlighting the need for safer, equally effective alternatives or improved formulations in the antifungal therapeutics market.

Key Market Trends

Increasing Prevalence of Fungal Infections:

The rising global incidence of fungal infections has become a defining trend in the growth of the Amphotericin B market. It is estimated that invasive fungal infections occur at a rate of approximately 6.5 million cases annually, leading to around 3.8 million deaths. Of these, an estimated 2.5 million fatalities-representing 68% (ranging between 35% and 90%)-are directly caused by these infections. Invasive aspergillosis alone affects over 2.1 million individuals annually, primarily among patients with chronic obstructive pulmonary disease (COPD), those in intensive care units, and individuals with hematologic malignancies or lung cancer. This condition has a concerning mortality rate of 85.2%. With the growing number of individuals affected by opportunistic and invasive fungal diseases, the demand for potent antifungal therapies such as Amphotericin B has significantly increased.

Key Market Players

  • Xiamen Neore Pharmaceutical Technology Co., Ltd
  • Concord Biotech Limited
  • United Biotech Pvt Ltd
  • Hubei Aoks Bio-Tech Co.,Ltd
  • Synbiotics Limited
  • North China Pharmaceutical Huasheng Co., Ltd
  • Xi'an Sonwu Biotech Co., Ltd.
  • Century Pharmaceutical Ltd
  • Xellia Pharmaceuticals

Report Scope

In this report, the Global Amphotericin B Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amphotericin B Market, By Sales Channel:

  • Direct
  • Indirect

Amphotericin B Market, By End Use:

  • Systemic Fungal Infections
  • Candidiasis
  • Aspergillosis
  • Mucormycosis
  • Leishmaniasis
  • Others

Amphotericin B Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amphotericin B Market.

Available Customizations:

Global Amphotericin B Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Amphotericin B Market

5. Global Amphotericin B Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Systemic Fungal Infections, Candidiasis, Aspergillosis, Mucormycosis, Leishmaniasis, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Amphotericin B Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Amphotericin B Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Amphotericin B Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Amphotericin B Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Amphotericin B Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Amphotericin B Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Amphotericin B Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Amphotericin B Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Amphotericin B Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Amphotericin B Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Amphotericin B Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Amphotericin B Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Amphotericin B Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Amphotericin B Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Amphotericin B Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Amphotericin B Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Amphotericin B Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Amphotericin B Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Amphotericin B Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Amphotericin B Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Amphotericin B Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Amphotericin B Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Amphotericin B Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Amphotericin B Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Amphotericin B Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Xiamen Neore Pharmaceutical Technology Co., Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Concord Biotech Limited
  • 15.3. United Biotech Pvt Ltd
  • 15.4. Hubei Aoks Bio-Tech Co.,Ltd
  • 15.5. Synbiotics Limited
  • 15.6. North China Pharmaceutical Huasheng Co., Ltd
  • 15.7. Xi'an Sonwu Biotech Co., Ltd.
  • 15.8. Century Pharmaceutical Ltd
  • 15.9. Xellia Pharmaceuticals

16. Strategic Recommendations

17. About Us & Disclaimer